Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Buy

Price to Earnings Rating

Strong Buy

Analyst Rating

Buy

Simple Moving Average

Strong Sell

Exponential Moving Average

Strong Sell

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Neutral

B

Sana Biotechnology, Inc. Common Stock (SANA)

Biological Products, (no Disgnostic Substances)

https://www.sana.com

Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. Its operations include identifying and developing potential product candidates, executing preclinical studies, establishing manufacturing capabilities, acquiring technology, organizing and staffing the Company, business planning, establishing the company's intellectual property portfolio, raising capital, and providing general and administrative support for these operations.

188 EAST BLAINE STREET, SUITE 400
SEATTLE, WA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

02/04/2021

Market Cap

1,113,442,330

Shares Outstanding

197,130,000

Weighted SO

197,133,208

Total Employees

N/A

Upcoming Earnings

08/01/2024

Similar Tickers

OLMA --.--%

CGEM --.--%

LIFE --.--%

ZNTL --.--%

XFOR --.--%

GRTX --.--%

TERN --.--%

DAWN --.--%

HOOK --.--%

Beta

1.4510

Last Div

0.0000

Range

2.745-12.0

Chg

0.0150

Avg Vol

1774474

Mkt Cap

1113442330

Exch

NASDAQ

Country

US

Phone

206 701 7914

DCF Diff

4.8091

DCF

0.1709

Div Yield

0.0000

P/S

0.0000

EV Multiple

-4.9355

P/FV

3.4547

Div Yield %

0.0000

P/E

-4.7912

PEG

1.3511

Payout

0.0000

Current Ratio

5.1974

Quick Ratio

5.1974

Cash Ratio

2.7381

DSO

0.0000

DIO

0.0000

Op Cycle

0.0000

DPO

70.7893

CCC

0.0000

Gross Margin

0.0000

Op Margin

0.0000

Pretax Margin

0.0000

Net Margin

0.0000

Eff Tax Rate

-0.0340

ROA

-0.3958

ROE

-0.7160

ROCE

-0.4175

NI/EBT

1.0000

EBT/EBIT

1.0328

EBIT/Rev

0.0000

Debt Ratio

0.1593

D/E

0.2902

LT Debt/Cap

0.2068

Total Debt/Cap

0.2249

Int Coverage

0.0000

CF/Debt

-2.4319

Equity Multi

1.8215

Rec Turnover

0.0000

Pay Turnover

5.1561

Inv Turnover

0.0000

FA Turnover

0.0000

Asset Turnover

0.0000

OCF/Share

-1.0224

FCF/Share

-1.2151

Cash/Share

1.0897

OCF/Sales

0.0000

FCF/OCF

1.1885

CF Coverage

-2.4319

ST Coverage

-23.9730

CapEx Coverage

-5.3050

Div&CapEx Cov

-5.3050

P/BV

3.4547

P/B

3.4547

P/S

0.0000

P/E

-4.7912

P/FCF

-3.9087

P/OCF

-4.8955

P/CF

-4.8955

PEG

1.3511

P/S

0.0000

EV Multiple

-4.9355

P/FV

3.4547

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. May 04, 20:00 SANA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sana Biotechnology, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit GlobeNewswire Inc. Apr 27, 20:00 EU INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that enCore Energy Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit GlobeNewswire Inc. Apr 12, 17:20 ROSEN, LEADING INVESTOR COUNSEL, Encourages Sana Biotechnology, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SANA GlobeNewswire Inc. Apr 06, 02:35 ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Sana Biotechnology, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SANA GlobeNewswire Inc. Apr 03, 01:09 ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Sana Biotechnology, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SANA GlobeNewswire Inc. Mar 30, 20:00 SANA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sana Biotechnology, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit GlobeNewswire Inc. Nov 17, 09:00 Uppsala University Hospital and Sana Biotechnology Announce Authorization of the First-in-Human Clinical Trial Application for a Primary Islet Cell Treatment for Patients with Type 1 Diabetes

Revenue Product Segmentation